Screening of Investigational Therapeutics to Treat, Modify or Prevent Epilepsy for the NINDS Epilepsy Therapy Screening Program (ETSP)

The National Institute of Neurological Disorders and Stroke (NINDS) is seeking information from qualified sources to perform preclinical pharmacological evaluations of potential therapeutic agents for the treatment of epilepsy. The contractor will be required to conduct studies evaluating investigational compounds in established workflow testing for drug-resistant epilepsy, disease prevention and modification assays, and pharmacokinetic studies. The contractor will also be required to perform human-based and ancillary studies to support the evolving requirements of the ETSP. Some key points to consider: • The contractor must have experience in preclinical pharmacological evaluations of potential therapeutic agents. • The contractor must have the capability to conduct studies in established workflow testing for drug-resistant epilepsy. • The contractor must have the capability to conduct studies in disease prevention and modification assays. • The contractor must have the capability to conduct pharmacokinetic studies. • The contractor must have the capability to perform human-based and ancillary studies.